BOZEMAN, Mont.and VANCOUVER, BC, February 3, 2023 /PRNewswire/ – Microbion Corporation, a clinical-stage pharmaceutical company, today announced that Karim LaljiCEO of Microbion Pharma Corp., will present at BIO CEO & Investor Conference 2023 in New York, NY. The conference will take place February 6e at 9e at the Marriott Marquis Times Square.
At the conference, Mr. Lalji will provide an update on Microbion’s clinical development programs for pravibisman, the company’s lead drug candidate and the first in a new class of drugs designated by the World Health Organization ( WHO). The presentation will highlight how pravibismane’s multiple new modes of activity can address the critical unmet needs of patients with nontuberculous mycobacteria (NTM) and cystic fibrosis lung infections, diabetic foot infections, orthopedic and other diseases.
Presentation details:
The presentation of Microbion will take place on February 6 at 3:45 p.m. ET in the conservatory room, 6e floor of the Marriot Marquis Times Square.
Private meetings with Microbion can be arranged via the BIO CEO & Investor Conference meeting platform or via the contact details below.
About Microbion
Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has multiple innovative modes of activity with unique potential to address unmet needs in chronic and serious diseases. The Company is advancing inhaled pravibisman into Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Topical/local pravibismane is in phase 2 development for the treatment of chronic wounds and orthopedic infections. Pravibismane has received support from the Cystic Fibrosis Foundation, NIH, US DoD and CARB-X with over $21 million in grants. The FDA has granted pravibismaniac Orphan Drug, Fast Track, and QIDP designations.
For more information, visit: www.microbioncorp.com.
Safe Harbor Statement
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of the clinical development of pravibismane and the preparation for possible commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace we expect; the size and growth of potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval for pravibisman or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibisman or any future product candidates. Actual results or developments may differ materially from those projected or implied by such forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Microbion Corporation
